Our healthcare experts have found PD-1/PD-L1 immunotherapy to be one of the most rapidly adopted therapies, and the global market for PD-1/PD-L1 immunotherapy is predicted to grow at a CAGR of 10.72% over the forecast period of 2020-2030.
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
Global Viral and Non-Viral Vector Manufacturing Market.pdfBIS Research Inc.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
Global Viral and Non-Viral Vector Manufacturing MarketBIS Research Inc.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.
Stem Cell Manufacturing Market PPT: Overview, Dynamics, Trends, Segmentation,...IMARC Group
The global stem cell manufacturing market size reached US$ 13.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 25.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.1% during 2024-2032.
More Info:- https://www.imarcgroup.com/stem-cell-manufacturing-market
The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.
The global biomaterials market was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031.
Cell and Gene Therapy Market - Growth Analysis & TrendsBIS Research Inc.
The cell and gene therapy industry analysis by BIS Research projects the market to grow at a significant CAGR of 36.52% during the forecast year 2019-25
Global Viral and Non-Viral Vector Manufacturing Market.pdfBIS Research Inc.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
Global Viral and Non-Viral Vector Manufacturing MarketBIS Research Inc.
The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.
The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.
Stem Cell Manufacturing Market PPT: Overview, Dynamics, Trends, Segmentation,...IMARC Group
The global stem cell manufacturing market size reached US$ 13.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 25.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.1% during 2024-2032.
More Info:- https://www.imarcgroup.com/stem-cell-manufacturing-market
The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031.
The global biomaterials market was valued at $122.92 billion in 2020 and is expected to reach $725.88 billion by 2031, growing at a CAGR of 17.98% between 2021 and 2031.
Global Hematological Malignancies Emerging Therapeutics Market.pdfBIS Research Inc.
The global hematological malignancies emerging therapeutics industry analysis by BIS Research projects the market to grow at a significant CAGR of 14.20% during the forecast period 2021-2031.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Aseptic Pharma Processing Market - Global and Regional AnalysisBIS Research Inc.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Next Generation Gynecological Cancer Diagnostics Market.pdfBIS Research Inc.
Next-Generation Gynecological Cancer Diagnostics market to grow at a significant CAGR of 10.07% during 2020-2031. Next-Generation Gynecological Cancer Diagnostics market report by BIS Research provides deep market insight, industry analysis, trends & forecast to 2031 that will help your business to grow.
3D Bioprinting Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and O...IMARC Group
According to the latest report by IMARC Group,finds that the global 3D bioprinting market reached a value of US$ 933.9 Million in 2021.3D bioprinting refers to the medical application of 3D printers for fabricating biological tissues and organs through the layering of living cells. It creates spatially-controlled patterns in 3D where viability and cell function are conserved within the printed construct. 3D bioprinting utilizes a layer-by-layer method to deposit materials like bio-inks. Bio-inks are obtained from living cells, biomaterials, and active biomolecules to create the 3D structure of tissues and organs.
Biodefense Market PPT 2021-26 | Enhancing Huge Growth and Latest Trends by T...IMARC Group
According to the latest report by IMARC Group,the global biodefense market size reached US$ 12.7 Billion by 2020.
Biodefense includes the utilization of several medical and military measures that are taken to safeguard individuals against bioterrorism.
Organ-on-chip Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...IMARC Group
The global organ-on-chip market size reached US$ 61.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 541.8 Million by 2032, exhibiting a growth rate (CAGR) of 26.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/organ-on-chip-market
Pediatric Genetic Testing Market - Global Analysis & ForeacstBIS Research Inc.
A large number of companies are emerging and competing to establish their dominance in the global pediatric genetic testing market. The companies in the market are undergoing significant activities to expand their market presence and establish their position in the global market.
PPT: Medical Cyclotron Market to Witness Huge Growth during 2022-2027IMARC Group
According to the latest report by IMARC Group, the global medical cyclotron market reached a value of US$ 192.6 Million in 2021. Medical cyclotron represents a type of particle accelerator, wherein an alternating electric field propels a beam of charged units in a spiral pattern. This assists in producing protons and radioactive isotopes for medical imaging, diagnosis, and treatment of various cardiovascular disorders.
The somatic genetic testing market is expected to grow at a CAGR of 9.30% during the forecast period from 2020 to 2030. The market is projected to reach $16.79 billion by the end of 2030.
Therapeutic Vaccines Market Growth, Demand and Challenges of the Key Industry...IMARC Group
The global therapeutic vaccines market size reached US$ 31.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 71.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/therapeutic-vaccines-market
Electrophysiology Market is Expected to Witness Rapid Growth by 2030 | Johnso...Future Market Insights
Rising incidences of cardiac problems have prompted electrophysiology device vendors to launch products which are technologically superior, allowing healthcare providers to administer effective treatment to patients. Techniques such as live 3D-mapping and radiofrequency ablation are being increasingly incorporated into electrophysiology devices.
Liquid Biopsy - TOC, Industry Report By Products and Services, Therapeutic Ap...BIS Research Inc.
This document provides an overview and analysis of the Latin America liquid biopsy market from 2019-2025. It discusses key market drivers such as the potential of liquid biopsy and growing prominence of precision medicine. The market is segmented by product type, circulating biomarkers, clinical applications, therapeutic applications, and country. Major companies discussed include Biocept, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Guardant Health, Illumina, and Qiagen N.V. The Latin America liquid biopsy market is expected to grow from $XX million in 2017 to $XX million in 2025 with increasing adoption for treatment monitoring, prognosis, and screening applications. Brazil, Mexico, and Argentina are identified as the largest country markets.
Refurbished Medical Imaging Equipment Market To Surpass $21.14 Billion By 202...OliviaThomas57
The global refurbished medical imaging equipment market was valued at USD 11.7 billion in 2019 and size is expected to reach USD 21.14 billion by 2027 to grow at a CAGR of 7.7% during the forecast period
Biobanking Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opport...IMARC Group
The global biobanking market size reached US$ 57.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 82.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.86% during 2023-2028.
More Info:- https://www.imarcgroup.com/biobanking-market
Global Minimally Invasive Neurosurgical Systems MarketBIS Research Inc.
The global market for minimally invasive neurosurgical systems is estimated to grow at a CAGR of 11.9% over the period 2020-2030 and generate $1217.4 million by the end of 2030.
Human Insulin Market Growth, Demand and Challenges of the Key Industry Player...IMARC Group
The global human insulin market size reached US$ 48.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 84.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.
More Info:- https://www.imarcgroup.com/human-insulin-market
Webinar Presentation Syndromic Testing – A New Take on Diagnosing Infectious ...BIS Research Inc.
The document summarizes a webinar on syndromic testing for diagnosing infectious diseases. The webinar featured several speakers who discussed topics like: how syndromic testing can provide faster results and reduce antibiotic use compared to traditional testing; applications of metagenomics next-generation sequencing (mNGS) in clinical diagnostics and its benefits; key trends in the syndromic testing market like high growth rates and the dominance of respiratory disease testing currently. The global syndromic testing market is expected to grow from $1.28 billion in 2022 to $3.25 billion in 2033, driven by factors like rising infectious disease incidence and the need for early diagnosis.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
More Related Content
Similar to Global PD-1 and PD-L1 Immunotherapy Market
Global Hematological Malignancies Emerging Therapeutics Market.pdfBIS Research Inc.
The global hematological malignancies emerging therapeutics industry analysis by BIS Research projects the market to grow at a significant CAGR of 14.20% during the forecast period 2021-2031.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
The global precision medicine market is expected to reach $278.61 billion by the end of 2030. The market is projected to grow at a CAGR of 11.13% during the forecast period, 2020-2030.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Aseptic Pharma Processing Market - Global and Regional AnalysisBIS Research Inc.
The global aseptic pharma processing market was valued to be $10,633.3 million in 2020 and is expected to reach $24,364.0 million by 2031, witnessing a CAGR of 7.90% during the forecast period 2021-2031.
Next Generation Gynecological Cancer Diagnostics Market.pdfBIS Research Inc.
Next-Generation Gynecological Cancer Diagnostics market to grow at a significant CAGR of 10.07% during 2020-2031. Next-Generation Gynecological Cancer Diagnostics market report by BIS Research provides deep market insight, industry analysis, trends & forecast to 2031 that will help your business to grow.
3D Bioprinting Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and O...IMARC Group
According to the latest report by IMARC Group,finds that the global 3D bioprinting market reached a value of US$ 933.9 Million in 2021.3D bioprinting refers to the medical application of 3D printers for fabricating biological tissues and organs through the layering of living cells. It creates spatially-controlled patterns in 3D where viability and cell function are conserved within the printed construct. 3D bioprinting utilizes a layer-by-layer method to deposit materials like bio-inks. Bio-inks are obtained from living cells, biomaterials, and active biomolecules to create the 3D structure of tissues and organs.
Biodefense Market PPT 2021-26 | Enhancing Huge Growth and Latest Trends by T...IMARC Group
According to the latest report by IMARC Group,the global biodefense market size reached US$ 12.7 Billion by 2020.
Biodefense includes the utilization of several medical and military measures that are taken to safeguard individuals against bioterrorism.
Organ-on-chip Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...IMARC Group
The global organ-on-chip market size reached US$ 61.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 541.8 Million by 2032, exhibiting a growth rate (CAGR) of 26.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/organ-on-chip-market
Pediatric Genetic Testing Market - Global Analysis & ForeacstBIS Research Inc.
A large number of companies are emerging and competing to establish their dominance in the global pediatric genetic testing market. The companies in the market are undergoing significant activities to expand their market presence and establish their position in the global market.
PPT: Medical Cyclotron Market to Witness Huge Growth during 2022-2027IMARC Group
According to the latest report by IMARC Group, the global medical cyclotron market reached a value of US$ 192.6 Million in 2021. Medical cyclotron represents a type of particle accelerator, wherein an alternating electric field propels a beam of charged units in a spiral pattern. This assists in producing protons and radioactive isotopes for medical imaging, diagnosis, and treatment of various cardiovascular disorders.
The somatic genetic testing market is expected to grow at a CAGR of 9.30% during the forecast period from 2020 to 2030. The market is projected to reach $16.79 billion by the end of 2030.
Therapeutic Vaccines Market Growth, Demand and Challenges of the Key Industry...IMARC Group
The global therapeutic vaccines market size reached US$ 31.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 71.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/therapeutic-vaccines-market
Electrophysiology Market is Expected to Witness Rapid Growth by 2030 | Johnso...Future Market Insights
Rising incidences of cardiac problems have prompted electrophysiology device vendors to launch products which are technologically superior, allowing healthcare providers to administer effective treatment to patients. Techniques such as live 3D-mapping and radiofrequency ablation are being increasingly incorporated into electrophysiology devices.
Liquid Biopsy - TOC, Industry Report By Products and Services, Therapeutic Ap...BIS Research Inc.
This document provides an overview and analysis of the Latin America liquid biopsy market from 2019-2025. It discusses key market drivers such as the potential of liquid biopsy and growing prominence of precision medicine. The market is segmented by product type, circulating biomarkers, clinical applications, therapeutic applications, and country. Major companies discussed include Biocept, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Guardant Health, Illumina, and Qiagen N.V. The Latin America liquid biopsy market is expected to grow from $XX million in 2017 to $XX million in 2025 with increasing adoption for treatment monitoring, prognosis, and screening applications. Brazil, Mexico, and Argentina are identified as the largest country markets.
Refurbished Medical Imaging Equipment Market To Surpass $21.14 Billion By 202...OliviaThomas57
The global refurbished medical imaging equipment market was valued at USD 11.7 billion in 2019 and size is expected to reach USD 21.14 billion by 2027 to grow at a CAGR of 7.7% during the forecast period
Biobanking Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opport...IMARC Group
The global biobanking market size reached US$ 57.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 82.3 Billion by 2028, exhibiting a growth rate (CAGR) of 5.86% during 2023-2028.
More Info:- https://www.imarcgroup.com/biobanking-market
Global Minimally Invasive Neurosurgical Systems MarketBIS Research Inc.
The global market for minimally invasive neurosurgical systems is estimated to grow at a CAGR of 11.9% over the period 2020-2030 and generate $1217.4 million by the end of 2030.
Human Insulin Market Growth, Demand and Challenges of the Key Industry Player...IMARC Group
The global human insulin market size reached US$ 48.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 84.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.
More Info:- https://www.imarcgroup.com/human-insulin-market
Similar to Global PD-1 and PD-L1 Immunotherapy Market (20)
Webinar Presentation Syndromic Testing – A New Take on Diagnosing Infectious ...BIS Research Inc.
The document summarizes a webinar on syndromic testing for diagnosing infectious diseases. The webinar featured several speakers who discussed topics like: how syndromic testing can provide faster results and reduce antibiotic use compared to traditional testing; applications of metagenomics next-generation sequencing (mNGS) in clinical diagnostics and its benefits; key trends in the syndromic testing market like high growth rates and the dominance of respiratory disease testing currently. The global syndromic testing market is expected to grow from $1.28 billion in 2022 to $3.25 billion in 2033, driven by factors like rising infectious disease incidence and the need for early diagnosis.
The global sustainable steel market is projected to reach $795.8 billion by 2031 from $327.3 billion in 2021, growing at a CAGR of 8.97% during the forecast period 2022-2031. The growth in the global sustainable steel market is expected to be driven by stringent government regulations, carbon neutrality targets, energy and cost efficiency owing to the use of recycled steel, and a significant increase in steel demand with the scarcity of raw materials and energy.
Cybersecurity in Automotive Connected Vehicles and Growing Security Vulnerabi...BIS Research Inc.
• Agenda:
o To evaluate various security vulnerabilities in connected vehicles.
o To analyze the initiatives taken and regulations implemented to address security vulnerabilities.
o To analyze the various types of cybersecurity solutions being developed or offered for the security of connected vehicles.
o To evaluate the major players in the ecosystem.
Report Preview is available at: https://bisresearch.com/industry-report/global-automotive-cybersecurity-market.html
BIS Research conducted a webinar on Carbon Neutral Data Center PracticesBIS Research Inc.
Agenda:
To evaluate various emerging trends in Data center industry.
To analyze the initiatives taken and regulations implemented to increase sustainable practices.
To analyze the various types of technologies currently deployed.
To evaluate the major players in the ecosystem.
Speaker Profiles:
Name: JD Enright, Sr.
Designation: Chief Operating Officer
Company: TMGcore Inc.
Experienced and dedicated business professional with 29 years working with DOD, Multinational Private and Public sector organizations. Primary focus on developing and executing Strategic Step-Up Growth initiatives in Emerging Markets, and Technologies. Specialized leadership in developing improved business operations to include Financial and Operational efficiencies. Implementation of next generation HPC Platforms, Global Blockchain Development Strategies, Biotechnology, Viral Cell and Gene Therapies and Market Intelligence Assimilation for public applications.
Webinar by BIS Research on Precision Oncology BiomarkersBIS Research Inc.
Precision oncology biomarkers are essential tools for tailoring cancer treatment to individual patients, as they provide insights into tumor biology and guide the selection of targeted therapies.
BIS conducted a deep intelligence webinar on the state-of-the-art technologies and emerging strategies used through the precision oncology biomarkers.
Direct-to-Customer Wellness | A Webinar on the Growing Need for Personalized ...BIS Research Inc.
Direct-to-consumer (DTC) wellness testing industry witnessed a strong emphasis on consumer health and wellness, instigating industry stakeholders to discover new revenue streams.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging trends in the healthcare sector, among several other industry verticals. In the bid to do the same, BIS is conducting a deep intelligence webinar on the increasing focus of DTC wellness programs in the healthcare sector.
Read Related Reports Overview at:
https://bisresearch.com/industry-report/global-direct-to-consumer-genetic-testing-market.html
https://bisresearch.com/industry-report/us-dtc-wellness-testing-market.html
Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Bat...BIS Research Inc.
The efficiency of the battery system in any electric vehicle (EV) determines its cost and vehicle performance. Challenges, such as range anxiety and charging time, have been a hindrance to increasing EV sales.
As a leading market intelligence firm, BIS Research strives to stay on top of the latest emerging technologies in the mobility sector, among several other industry verticals.
In the bid to do the same, BIS is conducting a deep intelligence webinar on the current paradigm shift happening for battery technologies in electric vehicles.
Here are all the details:
Webinar Topic: Emerging Battery Chemistries | Reimagining EVs Beyond Conventional Li-Ion Batteries
Webinar on AI in Medical Diagnosis with Emerging TechnologiesBIS Research Inc.
Artificial Intelligence (AI) is a rapidly growing field that has the potential to revolutionize the way medical diagnosis is performed. AI systems use advanced algorithms to analyze large amounts of data, such as medical images, patient histories, and lab results, to identify patterns and make predictions about patient outcomes.
In medical diagnosis, AI can be used in a variety of ways, including medical imaging, disease diagnosis, personalized treatment planning, and early disease detection. By leveraging the power of AI, healthcare providers can make faster and more accurate diagnoses, resulting in better patient outcomes.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Policy implications related to AI and digital transformation in healthcare.
• Initiatives taken and regulations implemented to address cybersecurity concerns.
• Major factors driving and hindering the growth of AI in medical devices diagnosis.
• Major players in the ecosystem
AI-Enabled Imaging Solutions Market - A Global Market Report by BIS ResearchBIS Research Inc.
The global AI-enabled medical imaging solutions market was valued at $1,854.5 million in 2022 and is anticipated to reach $18,356.5 million by 2032, witnessing a CAGR of 25.76% during the forecast period 2022-2032. you can get more info to visit this link..
https://bisresearch.com/industry-report/global-ai-enabled-medical-imaging-solutions-market.html
The global demand for achieving the net zero emission target by 2050 has pushed governments all over to adapt and adopt advanced carbon removal technologies to go carbon negative.
It is, indeed, an important topic of discussion, because a carbon free environment is the need of the hour to save our planet. And, therefore, BIS Research is glad to announce its upcoming webinar on this particular subject.
Agenda:
The main agenda of this webinar is to understand and explore the following:
• Primary sources of carbon emissions and associated environmental issues
• Carbon dioxide removal – key technology and adoption scenario
• Carbon dioxide removal (CDR): trends and key market developments
• Carbon dioxide removal as a credible solution
• Conclusion and future outlook
Webinar on Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy DevelopmentBIS Research Inc.
Agenda of the Webinar:
Cell and Gene Therapy Biomanufacturing Market: Trends and Key Developments
Awaited Technologies in the Cell and Gene Therapy Development
Regulatory Scenario – GMP/cGMP Guidelines
Biomanufacturing 4.0 - Adoption Scenario
Conclusion and Future Outlook
Sub-Orbital Testing Services Market Future Growth and Business Opportunities ...BIS Research Inc.
Sub-orbital platforms are increasing access to the near space-like environment for end users such as government agencies, research institutions, and commercial players.
The competitive landscape of the sub-orbital testing services market consists of several organic and inorganic strategies followed by the key players to increase their market share.
The space industry is continuously innovating and developing advanced technologies with the objective of enhancing space capabilities. The industry is gearing up to develop vehicles that entail a major feature, i.e., reusability.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
TOC - Global Military Robotic and Autonomous Systems (RAS) Market.pdfBIS Research Inc.
The robotic and autonomous system (RAS) is a multidisciplinary scientific and technological domain for implementing complex systems with cognitive capabilities.
RAS in military is being rigorously introduced and used in combat training. This has boosted the capabilities of armed units and subunits. The advent of artificial intelligence (AI) and its integration with military RAS has the potential to change future warfare.
Growing demand to increase warfighter lethality and remove soldiers from dangerous situations is propelling the global military RAS market.
Request for the sample of the report at: https://bisresearch.com/requestsample?id=1442&type=download
UAV Propulsion System Market Analysis, Statistics, Regional, and Forecast to ...BIS Research Inc.
UAV propulsion system manufacturers have also been inclined to counter the environment and other government regulations by developing sustainable propulsion, i.e., steps toward fossil-free aviation fuels and ion propulsion are a few of such significant innovations.
UAVs can be powered by a variety of different types of engines, including piston engines, turbine engines, Wankel engines, and electric and solar-powered engines.
The global UAV propulsion system market has witnessed a high growth rate in the last five to six years owing to its widespread applications across various industries, which were further bolstered by the COVID-19 pandemic.
Publication of BIS Research on UAV Propulsion System market has some great insights for UAV Propulsion Systems. Get free sample here: https://bisresearch.com/requestsample?id=1443&type=download
Fleet Management Market Trends, Key Players, Industry Analysis and Forecast 2...BIS Research Inc.
A fleet management system, which includes hardware, software and service, has the ability to make decisions for fleet managers and fleet businesses easily.
The ongoing research and development activities in this market are experiencing product launches of fleet management system for fleet owners, fleet managers, or businesses that utilize fleet management on a daily basis.
BIS Research has a new publication on Fleet Management, view free sample here : https://bisresearch.com/requestsample?id=1444&type=download
Agenda:
The main agenda of this webinar is to understand and explore the following:
• LoRaWAN adoption in agricultural applications as well as understanding the trends and key market developments.
• The significance of LoRaWAN in the field of IoT
• A comparative analysis between LoRaWAN and other IoT networks in terms of technology and capabilities.
• The impact of LoRaWAN on the operations of the agriculture industry and common use cases.
• The impact of the implementation of LoRaWAN technology on stakeholders in the agriculture ecosystem.
• The potential challenges that LoRaWAN might face in the future.
• The competitiveness of the market for LoRaWAN technology.
Augmented Reality in Agriculture Analysis and Statistics from 2022-2027BIS Research Inc.
AR depicts superimposing visual, audio, or other sensory data onto the physical world to improve one's experience. It is one of the most popular technological trends in today’s times. AR images can be displayed on a variety of devices, including eyeglasses and goggles, headsets, and heads-up displays such as helmet visors. As more smartphones, tablets, and other handheld devices that support AR are becoming available globally, the most popular way to use AR is on these devices in a variety of apps and games.
Although AR is used to visually communicate information, it is the integration of AR with other technologies that make it possible to adapt to precision farming and visual-based operations. Hence, farmers can utilize AR in combination with other technologies such as artificial intelligence (AI), big data, and the Internet of Things (IoT) to manage the rising food demand.
Get Augmented Reality in Agriculture report overview at: https://bisresearch.com/industry-report/ar-agriculture-market.html
Smart Harvest Market Generated Opportunities, Future Scope 2022-2027BIS Research Inc.
The growth in the global smart harvest market is expected to be driven by increasing smart farming practices among farmers, labor shortage, and growing government support for promoting the use of smart tech in the agriculture industry. Supported by government policies and technological developments, farmers and growers across the globe are expected to increase the implementation of smart harvest technologies. Moreover, the smart harvest market is witnessing several upcoming trends and opportunities, further propelling growth in the industry.
Get the PDF document on the technical aspects of Smart Harvest Market at: https://bisresearch.com/requestsample?id=1386&type=download
Precision Pest Management Market Leading Players, Development and Demand Fore...BIS Research Inc.
While farmers are losing crops due to pests, they have pressure to increase food production to feed the growing world population.
Precision pest management (PPM) is very important to avoid destruction caused by pests and to increase productivity. PPM helps to detect pests early with the help of crop monitoring so they can be controlled early to avoid further losses. The availability of advanced technologies and equipment has made agriculture automation more prevalent in developed countries.
To know more about the in-depth insights on precision pest management market, get PDF document: https://bisresearch.com/requestsample?id=1404&type=download
Agriculture Drones and Robots Market Growth Opportunity, Trends, Demand Analy...BIS Research Inc.
Agriculture drones and robots offer multiple benefits over conventional farming equipment, which is another factor driving the demand for these products in the agriculture industry. The adoption of agriculture drones and robots in commercial farms offers huge cost-saving opportunities.
Request for the Sample of the Report at: https://bisresearch.com/requestsample?id=1425&type=download
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
The best massage spa Ajman is Chandrima Spa Ajman, which was founded in 2023 and is exclusively for men 24 hours a day. As of right now, our parent firm has been providing massage services to over 50,000+ clients in Ajman for the past 10 years. It has about 8+ branches. This demonstrates that Chandrima Spa Ajman is among the most reasonably priced spas in Ajman and the ideal place to unwind and rejuvenate. We provide a wide range of Spa massage treatments, including Indian, Pakistani, Kerala, Malayali, and body-to-body massages. Numerous massage techniques are available, including deep tissue, Swedish, Thai, Russian, and hot stone massages. Our massage therapists produce genuinely unique treatments that generate a revitalized sense of inner serenely by fusing modern techniques, the cleanest natural substances, and traditional holistic therapists.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...nirahealhty
The South Beach Coffee Java Diet is a variation of the popular South Beach Diet, which was developed by cardiologist Dr. Arthur Agatston. The original South Beach Diet focuses on consuming lean proteins, healthy fats, and low-glycemic index carbohydrates. The South Beach Coffee Java Diet adds the element of coffee, specifically caffeine, to enhance weight loss and improve energy levels.
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Can Allopathy and Homeopathy Be Used Together in India.pdfDharma Homoeopathy
This article explores the potential for combining allopathy and homeopathy in India, examining the benefits, challenges, and the emerging field of integrative medicine.
MBC Support Group for Black Women – Insights in Genetic Testing.pdfbkling
Christina Spears, breast cancer genetic counselor at the Ohio State University Comprehensive Cancer Center, joined us for the MBC Support Group for Black Women to discuss the importance of genetic testing in communities of color and answer pressing questions.
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
Global PD-1 and PD-L1 Immunotherapy Market
1. All rights reserved at BIS Research
1
Global PD-1/PD-L1
Immunotherapy Market
Focus on Type, Application, Country Data
(14 Countries),
and Competitive Landscape:
Analysis and Forecast: 2019-2030
September 2020
TOC
3. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 3
Table of Contents
Executive Summary…………………………………………………………….20
1. Technology Definition.................................................................................31
1.1 Inclusion and Exclusion Criteria.......................................................32
1.1.1 Inclusions.............................................................................32
1.1.2 Exclusions ...........................................................................32
2. Market Scope ...............................................................................................33
2.1 Key Questions Answered in the Report...........................................35
3. Research Methodology ...............................................................................37
3.1 Primary Data Sources........................................................................38
3.2 Secondary Data Sources...................................................................39
3.3 Market Estimation Model...................................................................39
3.4 Criteria for Company Profiling..........................................................42
4. Market Overview..........................................................................................43
4.1 PD-1/PD-L1 Immunotherapy and Their Clinical Importance...........43
4.2 PD-1/PD-L1 Immunotherapy Development and Commercialization
Landscape ..........................................................................................44
4.3 Global PD-1/PD-L1 Immunotherapy Market and Growth Potential,
2019-2030............................................................................................46
4.4 Pricing and Reimbursement Scenario..............................................46
4.5 Impact of Patent Expiry and Entry of Biosimilars on Market .........47
4.6 Impact of COVID-19 on PD-1/PD-L1 Immunotherapy Market..........48
5. Epidemiology of PD-1/PD-L1 Immunotherapy ..........................................50
6. Patent Landscape........................................................................................59
7. Market Dynamics.........................................................................................61
7.1 Overview .............................................................................................61
7.2 Impact Analysis..................................................................................61
4. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 4
7.3 Drivers.................................................................................................62
7.3.1 Rising Prevalence of Cancer..............................................62
7.3.2 Unmet Medical Needs of Metastatic Cancer Patients.......64
7.3.3 Advancements Made in the Field of Precision Medicine
and Immuno-Oncology .......................................................64
7.3.4 Rising Awareness Among People for the Treatment of
Cancer ..................................................................................65
7.3.5 Increasing Research and Development Expenditure in the
Field of Oncology ................................................................66
7.3.6 Increase in Disposable Income ..........................................67
7.4 Restraints............................................................................................67
7.4.1 Adverse Effects of PD-1/PD-L1 Immunotherapy...............67
7.4.2 Payment Policy and Reimbursement Issue ......................69
7.4.3 High Development Cost of New Therapy ..........................69
7.5 Opportunities......................................................................................70
7.5.1 Developing Healthcare Infrastructure in Emerging
Economies ...........................................................................70
8. Industry Insights..........................................................................................71
8.1 Overview .............................................................................................71
8.2 Regulatory Scenario ..........................................................................71
8.3 Legal Requirements and Frameworks in the U.S. ...........................74
8.3.1 Clinical Trial Authorization .................................................74
8.3.2 Marketing Authorization .....................................................74
8.3.3 USFDA Guidelines for BLA Submission ...........................75
8.3.4 Post-Authorization Regulations.........................................77
8.4 Legal Requirements and Frameworks in Europe ............................77
8.4.1 EMA Biologics License Application Process....................78
8.4.2 Centralized Procedure ........................................................79
8.4.3 Decentralized Procedure ....................................................79
8.4.4 Mutual-Recognition Procedure ..........................................79
8.4.5 National Procedure..............................................................79
8.5 Legal Requirements and Frameworks in Asia-Pacific ....................80
5. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 5
8.5.1 China ....................................................................................80
8.5.2 Japan....................................................................................81
8.6 Expedited Regulatory Designations Around the World..................82
9. Global PD-1/PD-L1 Immunotherapy Market (by Type), $Million, 2019-2030
......................................................................................................................85
9.1 Introduction ........................................................................................85
9.2 PD-1 Inhibitors....................................................................................86
9.2.1 Commercialized Therapeutics............................................88
9.2.1.1 Keytruda...........................................................................89
9.2.1.2 Opdivo..............................................................................93
9.2.1.3 Libtayo .............................................................................97
9.2.2 Pipeline Therapeutics .........................................................98
9.3 PD-L1 Inhibitors ...............................................................................101
9.3.1 Commercialized Therapeutics..........................................102
9.3.1.1 Tecentriq........................................................................103
9.3.1.2 Imfinzi.............................................................................106
9.3.1.3 Bavencio ........................................................................107
9.3.2 Pipeline Therapeutics .......................................................109
10. Global PD-1/PD-L1 Immunotherapy Market (by Application), $Million,
2019-2030 ...................................................................................................111
10.1 Introduction ......................................................................................111
10.2 Non-Small Cell Lung Cancer (NSCLC) ...........................................112
10.3 Hepatocellular Carcinoma (HCC)....................................................116
10.4 Esophageal Cancer..........................................................................118
10.5 Small Cell Lung Cancer (SCLC)......................................................119
10.6 Urothelial Carcinoma .......................................................................121
10.7 Others................................................................................................124
11. Global PD-1/PD-L1 Immunotherapy Market (by Region), $Million, 2019-
2030 ............................................................................................................126
11.1 Overview ...........................................................................................126
6. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 6
11.2 North America ..................................................................................128
11.2.1 U.S. .....................................................................................131
11.2.2 Canada ...............................................................................132
11.3 Europe...............................................................................................134
11.3.1 Germany.............................................................................137
11.3.2 U.K. .....................................................................................138
11.3.3 France.................................................................................139
11.3.4 Italy .....................................................................................141
11.3.5 Spain...................................................................................142
11.3.6 Rest-of-Europe...................................................................143
11.4 Asia-Pacific.......................................................................................144
11.4.1 China ..................................................................................147
11.4.2 Japan..................................................................................148
11.4.3 India....................................................................................150
11.4.4 South Korea .......................................................................151
11.4.5 Australia.............................................................................152
11.4.6 Rest-of-APAC.....................................................................153
11.5 Latin America ...................................................................................154
11.5.1 Brazil...................................................................................157
11.5.2 Mexico ................................................................................158
11.5.3 Rest-of-Latin America .......................................................159
11.6 Rest-of-the-World.............................................................................160
12. Competitive Landscape ............................................................................162
12.1 Key Developments and Strategies .................................................162
12.1.1 Regulatory and Legal Developments...............................163
12.1.2 Partnerships, Alliances, and Business Expansions.......164
12.1.3 M&A Activities ...................................................................165
12.1.4 Funding Activities .............................................................166
12.2 Market Share Analysis.....................................................................167
13. Company Profiles......................................................................................169
13.1 Overview ...........................................................................................169
7. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 7
13.2 AstraZeneca Plc ...............................................................................170
13.2.1 Company Overview ...........................................................170
13.2.2 Role of AstraZeneca Plc in the Global PD-1/PD-L1
Immunotherapy Market.....................................................170
13.2.3 Financials...........................................................................172
13.2.4 Key Insights About Financial Health of the Company ...174
13.2.5 SWOT Analysis..................................................................175
13.3 BeiGene, Ltd.....................................................................................176
13.3.1 Company Overview ...........................................................176
13.3.2 Role of BeiGene, Ltd. in the Global PD-1/PD-L1
Immunotherapy Market.....................................................176
13.3.3 Financials...........................................................................178
13.3.4 Key Insights About Financial Health of the Company ...180
13.3.5 SWOT Analysis..................................................................181
13.4 Bristol-Myers Squibb Company......................................................182
13.4.1 Company Overview ...........................................................182
13.4.2 Role of Bristol Myers Squibb Company in the Global PD-
1/PD-L1 Immunotherapy Market.......................................182
13.4.3 Financials...........................................................................185
13.4.4 Key Insights About Financial Health of the Company ...186
13.4.5 SWOT Analysis..................................................................187
13.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.........................188
13.5.1 Company Overview ...........................................................188
13.5.2 Role of Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
in the Global PD-1/PD-L1 Immunotherapy Market..........188
13.5.3 Financials...........................................................................189
13.5.4 Key Insights About Financial Health of the Company ...190
13.5.5 SWOT Analysis..................................................................191
13.6 Eli Lilly & Company..........................................................................192
13.6.1 Company Overview ...........................................................192
13.6.2 Role of Eli Lilly & Company in the Global PD-1/PD-L1
Immunotherapy Market.....................................................192
13.6.3 Financials...........................................................................194
8. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 8
13.6.4 SWOT Analysis..................................................................196
13.7 F. Hoffmann-La Roche Ltd ..............................................................197
13.7.1 Company Overview ...........................................................197
13.7.2 Role of F. Hoffmann-La Roche Ltd. in the Global PD-1/PD-
L1 Immunotherapy Market................................................197
13.7.3 Financials...........................................................................199
13.7.4 Key Insights About Financial Health of the Company ...201
13.7.5 SWOT Analysis..................................................................202
13.8 GlaxoSmithKline plc ........................................................................203
13.8.1 Company Overview ...........................................................203
13.8.2 Role of GlaxoSmithKline plc in the Global PD-1/PD-L1
Immunotherapy Market.....................................................203
13.8.3 Financials...........................................................................205
13.8.4 Key Insights About Financial Health of the Company ...207
13.8.5 SWOT Analysis..................................................................208
13.9 Innovent Biologics, Inc....................................................................209
13.9.1 Company Overview ...........................................................209
13.9.2 Role of Innovent Biologics, Inc. in the Global PD-1/PD-L1
Immunotherapy Market.....................................................209
13.9.3 Financials...........................................................................211
13.9.4 Key Insights About Financial Health of the Company ...212
13.9.5 SWOT Analysis..................................................................213
13.10Jiangsu HengRui Medicine Co., Ltd. ..............................................214
13.10.1 Company Overview ...........................................................214
13.10.2 Role of Jiangsu HengRui Medicine Co., Ltd. in the Global
PD-1/PD-L1 Immunotherapy Market.................................214
13.10.3 Financials...........................................................................215
13.10.4 Key Insights About Financial Health of the Company ...216
13.10.5 SWOT Analysis..................................................................217
13.11Merck & Co., Inc. ..............................................................................218
13.11.1 Company Overview ...........................................................218
13.11.2 Role of Merck & Co., Inc. in the Global PD-1/PD-L1
Immunotherapy Market.....................................................218
9. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 9
13.11.3 Financials...........................................................................221
13.11.4 Key Insights About Financial Health of the Company ...223
13.11.5 SWOT Analysis..................................................................224
13.12Merck KGaA......................................................................................225
13.12.1 Company Overview ...........................................................225
13.12.2 Role of Merck KGaA in the Global PD-1/PD-L1
Immunotherapy Market.....................................................225
13.12.3 Financials...........................................................................227
13.12.4 Key Insights About Financial Health of the Company ...229
13.12.5 SWOT Analysis..................................................................230
13.13Novartis AG ......................................................................................231
13.13.1 Company overview............................................................231
13.13.2 Role of Novartis AG in the Global PD-1/PD-L1
Immunotherapy Market.....................................................231
13.13.3 Financials...........................................................................232
13.13.4 Key Insights About Financial Health of the Company ...234
13.13.5 SWOT Analysis..................................................................235
13.14Pfizer Inc. ..........................................................................................236
13.14.1 Company Overview ...........................................................236
13.14.2 Role of Pfizer Inc. in the Global PD-1/PD-L1
Immunotherapy Market.....................................................236
13.14.3 Financials...........................................................................238
13.14.4 SWOT Analysis..................................................................241
13.15Regeneron Pharmaceuticals Inc.....................................................242
13.15.1 Company Overview ...........................................................242
13.15.2 Role of Regeneron Pharmaceuticals, Inc. in the Global PD-
1/PD-L1 Immunotherapy Market.......................................242
13.15.3 Financials...........................................................................244
13.15.4 Key Insights About Financial Health of the Company ...245
13.15.5 SWOT Analysis..................................................................246
13.16Sanofi S.A. ........................................................................................247
13.16.1 Company Overview ...........................................................247
10. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 10
13.16.2 Role of Sanofi SA in the Global PD-1/PD-L1
Immunotherapy Market.....................................................247
13.16.3 Financials...........................................................................249
13.16.4 Key Insights About Financial Health of the Company ...251
13.16.5 SWOT Analysis..................................................................252
11. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 11
List of Figures
Figure 1: NCI Fiscal Budget Year-on-Year, 2013-2018...................................................................... 20
Figure 2: Financial Burden of Cancer (2015) ...................................................................................... 21
Figure 3: Share of Prevalence of Cancer in Global Population .......................................................... 22
Figure 4: Number of People with Cancer (by Age) in Global Population ........................................... 23
Figure 5: Global PD-1/PD-L1 Immunotherapy Market........................................................................ 24
Figure 6: Impact Analysis..................................................................................................................... 25
Figure 7: Share of Key Developments and Strategies, June 2015-June 2020.................................. 27
Figure 8: Global PD-1/PD-L1 Inhibitors Market (by Type), 2019 and 2030 ....................................... 28
Figure 9: Global PD-1/PD-L1 Inhibitors Market (by Application), 2019 and 2030 ............................. 29
Figure 10: Global PD-1/PD-L1 Inhibitors Market (by Region), 2019 and 2030.................................. 30
Figure 2.1: Global PD-1/PD-L1 Immunotherapy Market Segmentation............................................. 34
Figure 3.1: Global PD-1/PD-L1 Immunotherapy Market Methodology............................................... 37
Figure 3.2: Primary Research Methodology........................................................................................ 38
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis) .............................................................. 40
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)............................................................... 40
Figure 4.1: PD-1/PD-L1 Clinical Trial Landscape ............................................................................... 45
Figure 4.2: Global PD-1/PD-L1 Immunotherapy Market 2019-2030.................................................. 46
Figure 4.3: Most Impacted Practices in the Treatment of Cancer ...................................................... 49
Figure 5.1: Prevalence of Melanoma Cancer in U.S. (Total Population) ........................................... 52
Figure 5.2: Prevalence of Cervical Cancer in U.S. (Total Population) ............................................... 52
Figure 5.3: Prevalence of Lung Cancer in U.S. (Total Population)..................................................... 53
Figure 5.4: Prevalence of Renal Cell Carcinoma in U.S. (Total Population)...................................... 53
Figure 5.5: Prevalence of Squamous Cell Carcinoma of Head and Neck in U.S. (Total Population)54
Figure 5.6: Target Population of Lung Cancer in U.S. ........................................................................ 55
Figure 5.7: Target Population of Squamous Cell Carcinoma of Head and Neck in U.S. .................. 55
Figure 5.8: Target Population of Renal Cell Carcinoma in U.S. ......................................................... 56
Figure 5.9: Target Population of Melanoma in U.S............................................................................. 56
Figure 5.10: Target Population of Cervical Cancer in U.S.................................................................. 57
Figure 6.1: Number of Patents Filed, January 2015-December 2019................................................ 59
Figure 6.2: Percentage of Patents Filed, By Patent Office, January 2015-December 2019............. 60
Figure 7.1: Number of People with Cancer (by Age) in Global Population ........................................ 63
Figure 7.2: Household Disposable Income, US$/Capita .................................................................... 67
Figure 8.1: Steps for Obtaining Marketing Authorization .................................................................... 75
Figure 8.2: USFDA Review Timeline................................................................................................... 76
Figure 8.3: EMA Review Timeline ....................................................................................................... 78
12. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 12
Figure 9.1: Revenue Contribution of Different Segments, 2019 and 2030 ........................................ 85
Figure 9.2: Mechanism of Immunosuppression by PD-1/PD-L1 Axis ................................................ 87
Figure 9.3: Global PD-1/PD-L1 Inhibitors Market (by PD-1 Inhibitors), 2019-2030........................... 87
Figure 9.4: Global PD-1/PD-L1 Inhibitors Market (by PD-1 Inhibitors), 2019-2030........................... 88
Figure 9.5: Global PD-1 Inhibitors Market (Keytruda), 2019-2030 ..................................................... 93
Figure 9.6: Global PD-1 Inhibitors Market (Opdivo), 2019-2030 ........................................................ 97
Figure 9.7: Global PD-1 Inhibitors Market (Libtayo), 2019-2030........................................................ 98
Figure 9.8: Distribution of Drugs in Pipeline, by Phases..................................................................... 99
Figure 9.9: Global PD-1/PD-L1 Inhibitors Market (by PD-L1 Inhibitors), 2019-2030....................... 101
Figure 9.10: Global PD-1/PD-L1 Inhibitors Market (by PD-L1 Inhibitors), 2019-2030..................... 102
Figure 9.11: Global PD-L1 Inhibitors Market (Tecentriq), 2019-2030 .............................................. 105
Figure 9.12: Global PD-L1 Inhibitors Market (Imfinzi), 2019-2030 ................................................... 107
Figure 9.13: Global PD-L1 Inhibitors Market (Bavencio), 2019-2030............................................... 108
Figure 10.1: Revenue Contribution of Different Applications, 2019 and 2030................................. 111
Figure 10.2: Global PD-1/PD-L1 Inhibitors Market (NSCLC), 2019-2030........................................ 115
Figure 10.3: Global PD-1/PD-L1 Inhibitors Market (HCC), 2019-2030 ............................................ 117
Figure 10.4: Global PD-1/PD-L1 Inhibitors Market (Esophageal Cancer), 2019-2030.................... 119
Figure 10.5: Global PD-1/PD-L1 Inhibitors Market (Small Cell Lung Cancer), 2019-2030 ............. 121
Figure 10.6: Global PD-1/PD-L1 Inhibitors Market (Urothelial Carcinoma), 2019-2030.................. 124
Figure 10.7: Global PD-1/PD-L1 Inhibitors Market (Others), 2019-2030 ......................................... 125
Figure 11.1: Global PD-1/PD-L1 Immunotherapy Market (by Region)............................................. 126
Figure 11.2 Global PD-1/PD-L1 Immunotherapy Market (by Region), 2019-2030.......................... 127
Figure 11.3: North America PD-1/PD-L1 Immunotherapy Market, 2019-2030................................ 128
Figure 11.4: North America: Market Dynamics ................................................................................. 129
Figure 11.5: Revenue Contributions of Different Countries in North America, 2019 and 2030...... 130
Figure 11.6: U.S. PD-1/PD-L1 Immunotherapy Market, 2019-2030 ................................................ 131
Figure 11.7: Canada PD-1/PD-L1 Immunotherapy Market, 2019-2030........................................... 133
Figure 11.8: Europe PD-1/PD-L1 Immunotherapy Market, 2019-2030............................................ 134
Figure 11.9: Europe: Market Dynamics............................................................................................. 135
Figure 11.10: Revenue Contributions of Different Countries in Europe, 2019 and 2030 ................ 136
Figure 11.11: Germany PD-1/PD-L1 Immunotherapy Market, 2019-2030 ...................................... 137
Figure 11.12: U.K. PD-1/PD-L1 Immunotherapy Market, 2019-2030 .............................................. 139
Figure 11.13: France PD-1/PD-L1 Immunotherapy Market, 2019-2030.......................................... 140
Figure 11.14: Italy PD-1/PD-L1 Immunotherapy Market, 2019-2030............................................... 141
Figure 11.15: Spain PD-1/PD-L1 Immunotherapy Market, 2019-2030............................................ 142
Figure 11.16: Rest-of-Europe PD-1/PD-L1 Immunotherapy Market, 2019-2030 ............................ 143
Figure 11.17: Asia-Pacific PD-1/PD-L1 Immunotherapy Market, 2019-2030 .................................. 144
13. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 13
Figure 11.18: APAC: Market Dynamics............................................................................................. 145
Figure 11.19: Revenue Contributions of Different Countries in Asia-Pacific, 2019 and 2030......... 146
Figure 11.20: China PD-1/PD-L1 Immunotherapy Market, 2019-2030............................................ 148
Figure 11.21: Japan PD-1/PD-L1 Immunotherapy Market, 2019-2030 ........................................... 149
Figure 11.22: India PD-1/PD-L1 Immunotherapy Market, 2019-2030.............................................. 150
Figure 11.23: South Korea PD-1/PD-L1 Immunotherapy Market, 2019-2030................................. 151
Figure 11.24: Australia PD-1/PD-L1 immunotherapy market, 2019-2030 ....................................... 152
Figure 11.25: RoAPAC PD-1/PD-L1 immunotherapy market, 2019-2030....................................... 153
Figure 11.26: Latin America PD-1/PD-L1 Immunotherapy Market, 2019-2030............................... 155
Figure 11.27: Latin America: Market Dynamics ................................................................................ 155
Figure 11.28: Revenue Contributions of Different Countries in Latin America, 2019 and 2030..... 156
Figure 11.29: Brazil PD-1/PD-L1 Immunotherapy Market, 2019-2030 ............................................ 158
Figure 11.30: Mexico PD-1/PD-L1 Immunotherapy Market, 2019-2030.......................................... 159
Figure 11.31: Rest-of-Latin America PD-1/PD-L1 Immunotherapy Market, 2019-2030.................. 160
Figure 11.32: RoW PD-1/PD-L1 Immunotherapy Market, 2019-2030 ............................................. 161
Figure 12.1: Share of Key Developments and Strategies, June 2015-June 2020........................... 163
Figure 12.2: Regulatory and Legal Developments Share (by Company), June 2015-June 2020 . 164
Figure 12.3: Partnerships, Alliances, and Business Expansions (by Company), June 2015-June 2020
............................................................................................................................................................. 165
Figure 12.4: M&A Activities Share (by Company), June 2015-June 2020....................................... 166
Figure 12.5: Market Share Analysis (by Company), 2018 and 2019 ............................................... 167
Figure 13.1: Total Number of Companies Profiled............................................................................ 169
Figure 13.2: AstraZeneca Plc: Overall Product Portfolio .................................................................. 171
Figure 13.3: AstraZeneca plc: Overall Financials, 2017-2019.......................................................... 172
Figure 13.4: AstraZeneca plc: Revenue (by Segment), 2017-2019................................................. 173
Figure 13.5: AstraZeneca plc: Revenue (by Region), 2017-2019.................................................... 173
Figure 13.6: AstraZeneca plc: R&D Expenditure, 2017-2019 .......................................................... 174
Figure 13.7: AstraZeneca plc: SWOT Analysis................................................................................. 175
Figure 13.8: BeiGene, Ltd.: Overall Product Portfolio (Approved in China)..................................... 177
Figure 13.9: BeiGene, Ltd.: Overall Financials, 2017-2019.............................................................. 178
Figure 13.10: BeiGene, Ltd.: Revenue (by Region), 2017-2019...................................................... 179
Figure 13.11: BeiGene, Ltd.: R&D Expenditure, 2017-2019 ............................................................ 180
Figure 13.12: BeiGene, Ltd.: SWOT Analysis................................................................................... 181
Figure 13.13: Bristol Myers Squibb Company: Overall Product Portfolio......................................... 183
Figure 13.14: Bristol Myers Squibb Company: Overall Financials, 2017-2019 ............................... 185
Figure 13.15: Bristol Myers Squibb Company: Revenue (by Region), 2017-2019.......................... 185
Figure 13.16: Bristol Myers Squibb Company: R&D Expenditure, 2017-2019 ................................ 186
16. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 16
List of Tables
Table 1: Leading Players in Global PD-1/PD-L1 Immunotherapy Market.......................................... 26
Table 4.1: Clinical Studies About Pembrolizumab .............................................................................. 43
Table 4.2: Clinical Studies About Nivolumab ...................................................................................... 44
Table 4.3: Commercialized PD-1/PD-L1 Products.............................................................................. 45
Table 5.1: Type of Tumors Treated by PD-1/PD-L1 Immunotherapy ................................................ 50
Table 6.1: Share of Patents Filed, January 2015-December 2019.................................................... 60
Table 7.1: Impact Analysis ................................................................................................................... 62
Table 7.2: Comparison of R&D Expenditure by Major Pharmaceutical Companies, 2018 and 201966
Table 7.3: Most Common Side Effects to PD-1/PD-L1 Immunotherapy............................................ 68
Table 8.1: Regulatory Scenario Across the World .............................................................................. 71
Table 8.2: Expedited Regulatory Designations Around the World ..................................................... 82
Table 9.1: Keytruda Indications, Usage, and Dose............................................................................. 89
Table 9.2: Opdivo Indications, Usage, and Dose................................................................................ 94
Table 9.3: Libtayo Indications, Usage, and Dose................................................................................ 98
Table 9.4: Phase 2 - Pipeline PD-1 inhibitors...................................................................................... 99
Table 9.5: Phase 3 - Pipeline PD-1 inhibitors.................................................................................... 100
Table 9.6: Tecentriq Indications, Usage, and Dose .......................................................................... 103
Table 9.7: Imfinzi Indications, Usage, and Dose............................................................................... 106
Table 9.8: Bavencio Indications, Usage, and Dose .......................................................................... 108
Table 9.9: Phase 2 - Pipeline PD-1 inhibitors.................................................................................... 109
Table 9.10: Phase 3 - Pipeline PD-1 inhibitors.................................................................................. 110
Table 10.1: First Line Treatment Options, If Marker is Present: PD-L1 ≥1%................................... 113
Table 10.2: First Line Treatment for Adenocarcinomas, Large Cell and Unknown Types, if Marker is
Absent or Unknown ............................................................................................................................ 114
Table 10.3: Next-in-Line Treatment for Adenocarcinomas, Large Cell and Unknown Types, if Marker
is Absent or Unknown ........................................................................................................................ 114
Table 10.4: First Line Treatment for Squamous Cell Carcinoma if Marker is Absent or Unknown. 114
Table 10.5: Next-in-Line Treatment for Squamous Cell Carcinoma if Marker is Absent or Unknown
............................................................................................................................................................. 115
Table 10.6: PD-1/PD-L1 Inhibitors for the Treatment of HCC .......................................................... 116
Table 10.7: PD-1/PD-L1 Inhibitors for the Treatment of Esophageal Cancer.................................. 118
Table 10.8: PD-1/PD-L1 Inhibitors for the Treatment of Small Cell Lung Cancer ........................... 120
Table 10.9: PD-1/PD-L1 Inhibitors for the Treatment of Urothelial Carcinoma................................ 122
Table 13.1: AstraZeneca Plc: Pipeline Product Portfolio .................................................................. 171
Table 13.2: BeiGene, Ltd.: Pipeline Product Portfolio....................................................................... 177
18. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 18
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in
today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates
and institutions worldwide and assist them with market intelligence in the area of emerging
technologies, advisories, and other innovative solutions.
Know More Know More
Know More
Know More
19. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 19
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in
response to orders. The report is licensed for the customer's internal use only and is subject to
restrictions set henceforth. This document and its contents are confidential and may not be further
distributed, published or reproduced, in whole or in part, by any medium or in any form for any
purpose, without the written consent of BIS Research. The customer will not disclose the contents of
the report, whether directly through any medium or indirectly through incorporation in a database,
marketing list, report or otherwise, or use or permit the use of information to generate any statistical
or other information that is or will be provided to third parties, or voluntarily produce information in
legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information
is available. Any recommendation contained in this report may not be suitable for all investors or
businesses. The market conclusions drawn are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by BIS Research as of the date of such statements,
are inherently subject to market fluctuations and business, economic and competitive uncertainties
and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135
20. Global PD-1/PD-L1 Immunotherapy Market
All rights reserved at BIS Research 20
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: info@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544